FDA limits #JnJ vaccine to only those who can't receive other vaccines due to risk of thrombocytopenia syndrome (TTS), aka vaccine-induced thrombocytic thrombocytopenia (VITT), aka the rare vaccine clot syndrome we've known about since 3/2021
cnn.com/2022/05/05/hea…
The cause of this rare effect is the development of anti-PIF4 antibodies, but the mechanism of that is, surprisingly, still unknown. The same effect is seen in AZ, and J&J is Ad26 while AZ is a chimp Ad, so it's likely common to many-most primate adenoviruses.
It's been suggested Ad capsids bind and precipitate PIF4, triggering an immune reaction against PIF4. However a simpler mechanism that I have yet to see ruled out would be simply the production of antibodies to some Ad capsid protein that in rare cases cross-react to PIF4
The practical effect of today's FDA action is to remove J&J as a booster option for anyone still entertaining that.

That will leave Novavax as the only RNA alternative for boosters in the US, if FDA approves. Wonder how work on the Omicron-adapted Novavax booster is going.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Michael Lin, MD PhD 🧬

Michael Lin, MD PhD 🧬 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @michaelzlin

May 6
Taiwan is the latest place to get an Omicron wave (maybe the last place on earth to do so?), and I have been watching the rising case numbers with some trepidation.

The reason for concern is clear, but may surprise you: Only ~70% of seniors over 75yo are 2x vaccinated. Image
Yes Taiwan has been a model in avoiding SARSCoV2 via quarantine, contact-tracing, testing, and isolation. It has been correctly praised alongside New Zealand and Korea for that.

But the previous success hid a problem in vaccination. This matters now that Omicron has taken root.
In Taiwan the Omicron surge has taken hold, but very few deaths have been seen yet. For example today it's 36000 cases and 10 deaths (below thx to the excellent @cookiebandit)

But there's nothing to celebrate in those numbers, yet. (@cookiebandit knows)

Read 12 tweets
May 2
Time for a new vax. Even for hospitalization, VE of 3x Pfizer stops to ~55% after 3 months against Omicron

thelancet.com/journals/lanre…
This BTW shows it was incorrect to claim that CD8 T cells, which can target more parts of the spike protein, will guarantee cross-strain protection against severe disease even in the absence of high antibody levels. Very often hopeful ideas get traction without proof.
I should mention T cell levels decay slowly which was why the optimists hoped they could maintain cross-strain protection from severe disease for a long time. The decay in hosp VE against Omicron being faster than T cell decays indicates that antibodies are still most important.
Read 8 tweets
Apr 26
There's been some debate about whether annual SARSCoV2 deaths can be limited to flu-like numbers despite widespread immunity, if 1-2 new waves occur each year.

No need to debate, just look at numbers. NZ is a good model because it's 95% vaccinated (98% in elderly)
NZ death rates from Omicron have crested, so we can measure deaths from a SARSCOV2 variant wave when essentially everyone has immunity to an earlier variant.

We can look at both ascribed deaths and excess mortality, and we can compare a few countries
Death rates from flu are <10k per year in the US if you go by flu as the listed cause of death. But the way we ascribe deaths to flu actually count deaths from CV and respiratory problems soon after a flu infection, so it's really more like "with flu". This gets 20–60k per year.
Read 19 tweets
Apr 25
3rd minithread from ECCMID: In the same session as S-217622/ensitrelvir and anti-S DARPin/ensovibep, Merck presented molnupiravir (MOV) Ph3 virological outcomes. Results were less impressive, and no virological benefit seen in seropositive patients.
Viral RNA reduction vs. placebo at day 4 or 5 has been measured for all drugs, so can be used for comparison: Ensitrelvir: 0.41 logs (10⁰'⁴¹=2.6x) in 84% vaxxed
Ensovibep: 0.44 in 50% sero+
Paxlovid: 0.99 in sero–, 0.36 in sero+
Molnupiravir: ~0.4 in sero–, 0 in sero+
Viral levels start higher in sero–, so one can expect bigger reductions in sero– than sero+ (e.g. Paxlovid 0.99 in sero–, 0.36 in sero+).

But MOV benefit to sero– (0.4) is similar to the effects of other drugs on sero+, and MOV has no discernable benefit on sero+.
Read 16 tweets
Apr 25
At ECCMID, Molecular Partners and Novartis revealed Phase 2/3 results for ensovibep, a SARSCoV2 spike binder based on Pluckthun's synthetic DARPin domain. Ensovibep is smartly designed to mimic an antibody: 3 domains binding spike for avidity and 2 to HSA for half-life extension.
Ensovibep was given as a one-time IV injection within 7 days after symptom onset. Patients were both vaxxed and unvaxxed (although %'s not described). 50% had previous exposure to SARSCoV2.
Only primary endpoint was suppression of viral RNA titers. This was met. Ensovibep showed reductions in viral RNA of 0.34 to 0.61 logs, which makes it similar to Shionogi's drug.
Read 6 tweets
Apr 24
At ECCMID, Shionogi presented Phase 1, 2a, and 2b data for their SARSCoV2 protease inhibitor S-217622/ensitrelvir. This drug is dosed once daily. Unlike the 2x daily Paxlovid it doesn't require ritonavir which has many drug-drug interactions. A quick thread.
As the structure shows this is not a peptidomimetic. S217622 was discovered by HTS followed by structure-guided optimization. It binds the active site and partially fills S1 and S1'.

Showing how slow peer review usually is, it's still in preprint status.
biorxiv.org/content/10.110…
Testing in mostly vaxxed, ensitrelvir looks good on virologic endpoints. Here are results from the largest study (phase 2b). Note subjects were 84-87% vaxxed and median time from diagnosis to dosing is 3-4 days.
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(